Category Archives: Regulatory

FDA’s Patient Outreach: Finding Ties that Bind

Is the FDA doing enough to incorporate the patient perspective in the drug review process? This was the key question considered at a panel of regulatory experts held at last month’s annual BIO International Convention in San Diego. The consensus: while FDA deserves high marks for effort, both in reconciling the diversity of patient organization […]
Also posted in Events, FDA, Meetings, Op-Ed, Safety | Tagged , , , | Leave a comment

Making the Most of Social Media (Within FDA’s New Guidelines)

By Ken Ribotsky. Pharmaceutical companies have begun using social media for business needs and promotion, yet have been hesitant to become too engaged since the FDA’s stance on social media activity remained unclear. But now that we know the FDA’s specific guidelines for pharma companies’ actions online, it’s time for brands to consider diving into […]
Also posted in compliance, E-Media, FDA, Guest Blog, Op-Ed, social media | Tagged , | 1 Comment

FDA Warning to GSK Biologicals

FDA issued a warning letter to GlaxoSmithKline Biologicals (GSK), North America on June 12, 2014 for deviations from cCGMP requirements found during an inspection from Mar. 31 to Apr. 9, 2014 of its influenza vaccine manufacturing facility in Quebec. GSK is making progress in addressing FDA’s concerns and is working to meet supply commitments, the […]
Also posted in FDA | Tagged , , | Leave a comment

New Social Media Guidelines: What FDA Says, and What It Means

By Simon Beins is Associate Director, Strategy, Heartbeat Ideas & Heartbeat West. Earlier this year, FDA promised three sets of guidelines to clarify using social media for pharma marketing. Last week it delivered two of them The first, Internet/Social Media Platforms with Character Space Limitation—Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices, […]
Also posted in E-Media, FDA, Guest Blog, multimedia, social media | Tagged , , , , | Leave a comment

Q&A: Gauging Impact of Comparative Effectiveness Research

While at DIA’s 50th Annual Meeting, we got the chance to speak with Nancy Dreyer, chief of scientific affairs and senior VP at Quintiles Outcome, the CRO’s real-world and late-phase research division, about the current tide for comparative effectiveness research (CER). Dreyer is the leader of the GRACE Initiative, which has developed good practice principles for […]
Also posted in comparative effectiveness, Global, healthcare, Uncategorized | Tagged , , , , , | Leave a comment
  • Categories

  • Meta